Editas teases tiny sickle cell sample in effort to climb back into gene editing's upper echelon

Its been a rough and tumble 2022 for Editas Medicine, marked by a new executive team, the suspension of its lead asset and navigating a clinical hold on the efficacy portion of a sickle cell program.